Guardant Health (GH) director gains 154 shares through RSU vesting

Rhea-AI Filing Summary

Guardant Health director Steve Krognes reported a routine equity compensation event. On January 31, 2026, 154 Restricted Stock Units vested at an exercise price of $0, resulting in the acquisition of 154 shares of common stock. Following this transaction, he directly holds 18,899 shares of common stock and 772 Restricted Stock Units.

The vested RSUs come from an award granted on August 9, 2022, which vested 25% of the shares on June 30, 2023. The remaining 75% vests in substantially equal monthly installments over the three years after June 30, 2023.

Insider Trade Summary

154 shares exercised/converted

Mixed 2 txns

Insider Krognes Steve E.

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	154	$0.00	--
Exercise	Common Stock	154	$0.00	--

Holdings After Transaction: Restricted Stock Units — 772 shares (Direct); Common Stock — 18,899 shares (Direct)

Footnotes (1)

1. This represents a restricted stock unit award granted on August 9, 2022 that vested as to 25% of the shares subject to such award on June 30, 2023. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter. Not applicable for Restricted Stock Units.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Krognes Steve E.

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/31/2026		M		154	A	$0	18,899	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	01/31/2026		M			154	(1)	(2)	Common Stock	154	$0	772	D

Explanation of Responses:

1. This represents a restricted stock unit award granted on August 9, 2022 that vested as to 25% of the shares subject to such award on June 30, 2023. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter.

2. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John Saia, as attorney-in-fact for Steve Krognes	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Guardant Health (GH) director Steve Krognes report?

Steve Krognes reported a routine equity compensation transaction. On January 31, 2026, 154 Restricted Stock Units vested at $0 and converted into 154 shares of Guardant Health common stock, reflecting standard vesting under a previously granted RSU award.

How many Guardant Health (GH) shares does Steve Krognes own after this Form 4?

After the reported transaction, Steve Krognes directly owns 18,899 shares of Guardant Health common stock. In addition, he holds 772 Restricted Stock Units, which represent rights to receive future shares as they vest under the RSU award’s vesting schedule.

What was the size and price of the RSU vesting reported for Guardant Health (GH)?

The Form 4 shows 154 Restricted Stock Units vesting and converting into 154 shares of common stock. The transaction price per share was $0, consistent with RSUs, which typically convert into shares without cash payment when vesting conditions are satisfied.

When was the underlying Guardant Health (GH) RSU award granted to Steve Krognes?

The Restricted Stock Unit award was granted on August 9, 2022. According to the footnote, 25% of the shares vested on June 30, 2023, with the remaining 75% vesting in substantially equal monthly installments over the following three-year period.

How does the Guardant Health (GH) RSU vesting schedule for Steve Krognes work?

The award vested 25% of its shares on June 30, 2023. The remaining 75% vests in substantially equal monthly installments on each monthly anniversary of June 30, 2023, over three years, creating ongoing, gradual share delivery as time-based service conditions are met.

Is this Guardant Health (GH) Form 4 an open-market stock purchase or sale?

No, this Form 4 reflects an RSU vesting event coded “M,” not an open-market trade. 154 Restricted Stock Units converted into 154 common shares at $0, consistent with stock-based compensation rather than a discretionary buy or sell in the market.